No Benefit With Addition of Epacadostat in Pancreatic Cancer

Newsfeed Image, Light Gray Text On Dark Gray Background
 In findings from the phase I/II ECHO-203 study presented at the 2018 AACR Annual Meeting, there were no clinical responses demonstrated by adding the IDO1 inhibitor epacadostat to the PD-L1 inhibitor durvalumab (Imfinzi) in patients with pancreatic cancer.

This is the second setback for epacadostat this month. Previously reported findings from the phase III ECHO-301/KEYNOTE-252 trial showed that adding the IDO inhibitor to the PD-1 inhibitor pembrolizumab (Keytruda) failed to improve progression-free survival in patients with melanoma. Read more here . .